Skip to main content
SpringerLink
Log in

Amisulpride and Sulpiride in the Treatment of Psychosis

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 46 Accesses

Abstract

Amisulpride is a second-generation (atypical) antipsychotic primarily used to treat schizophrenia and bipolar disorder. In low dose it is also used to treat dysthymia. It blocks selectively postsynaptic dopamine D2 and D3 receptors, and in low doses presynaptic receptors. The efficacy in treatment of psychoses was established in randomized, double-blind, placebo-controlled studies and maintenance studies. Some meta-analyses found amisulpride more efficacious compared to other antipsychotics. Common side effects are induced by increase of prolactin level.

Sulpiride is a low-potent antipsychotic drug chemically and clinically similar to amisulpride. It is mainly used in the treatment of dysthymia, depressive disorder, and vertigo.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Aylward M, Maddock J, Dewland P, Lewis P. Sulpiride in depressive illness. Adv Biol Psychiatr. 1981;7:154–65.

    Article  Google Scholar 

  • Carrière P, Bonhomme D, Lempérière T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry. 2000;15:321–9.

    Article  PubMed  Google Scholar 

  • Cassano G, Castrogiovanni P, Conti L, Bonollo L. Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trail. Curr Ther Res. 1975;17:189–201.

    CAS  PubMed  Google Scholar 

  • Cohen LS, Viguera AC, McInerney KA, Freeman MP, et al. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for atypical antipsychotics. Am J Psychiatry. 2016;173:263–70.

    Article  PubMed  Google Scholar 

  • Colonna L, Guerault E, Turjanski S. Long-term study of amisulpride in the treatment of schizophrenia. Biol Psychiatry. 1997;42:181S.

    Article  Google Scholar 

  • Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol. 2000;15:13–22.

    Article  CAS  PubMed  Google Scholar 

  • Costa E, Silva JA. Comparative doubleblind study of amisulpride versus haloperidol in the treatment of acute psychotic states. In: Borenstein P, editor. Amisulpride. Paris: Expansion Scientifique Francaise; 1989. p. 93–104.

    Google Scholar 

  • Favennec C, Rein W, Turjanski S. The safety profile of amisulpride, an “atypical” antipsychotic. Eur Neuropsychopharmacol. 1996;6:S4–111.

    Article  Google Scholar 

  • Fleurot O, Bech P, Turjanski S. Amisulpride versus risperidone in the treatment of acute schizophrenia. Biol Psychiatry. 1997;42:194S.

    Article  Google Scholar 

  • Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14:2–44.

    Article  PubMed  Google Scholar 

  • Hiemke C, Bergemann N, Clement HW, Conca A, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.

    Article  CAS  Google Scholar 

  • Huybrechts KF, Hernández-Díaz S, Patorno E, Desai RJ, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiat. 2016;73:938–46.

    Article  Google Scholar 

  • Johnsen E, Kroken RA, Løberg EM, Rettenbacher M, et al. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. Lancet Psychiatry. 2020;7:945–54.

    Article  PubMed  Google Scholar 

  • Kahn RS, Fleischhacker WW, Boter H, Davidson M, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–97.

    Article  CAS  PubMed  Google Scholar 

  • Kogeorgos J, Kanellos P, Michalakeas A, Ioannidis J. Sulpiride and risperidone vs. “classical neuroleptics” in schizophrenia: a follow-up study. Eur Neuropsychopharmacol. 1995;5:335–6.

    Article  Google Scholar 

  • Komossa K, Rummel-Kluge C, Hunger H, Schmid F, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006624.

    Google Scholar 

  • Krause M, Zhu Y, Huhn M, Schneider-Thoma J, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268:625–39.

    Article  PubMed  Google Scholar 

  • Lai EC, Chang CH, Kao Yang YH, Lin SJ, Lin CY. Effectiveness of sulpiride in adult patients with schizophrenia. Schizophr Bull. 2013;39:673–83.

    Article  PubMed  Google Scholar 

  • Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord. 1997;43:95–103.

    Article  CAS  PubMed  Google Scholar 

  • Lecrubier Y, Azorin M, Bottai T, Dalery J, et al. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology. 2001;44:41–6.

    Article  CAS  PubMed  Google Scholar 

  • Lepola U, Koskinen T, Rimón R, Salo H, Gordin A. Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. Acta Psychiatr Scand. 1989;80:92–6.

    Article  CAS  PubMed  Google Scholar 

  • Leucht S, Cipriani A, Spineli L, Mavridis D, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.

    Article  CAS  Google Scholar 

  • Levine M, Ruha AM. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS Drugs. 2012;26:601–11.

    Article  CAS  PubMed  Google Scholar 

  • Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry. 1997;170:18–22.

    Article  CAS  PubMed  Google Scholar 

  • Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V. Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics. Eur J Pharmacol. 1994;256:211–4.

    Article  CAS  PubMed  Google Scholar 

  • Malm H, Folk ME, Lahesmaa-Korpinen A-M. Safety of the second generation antipsychotics during pregnancy. Reprod Toxicol. 2018;80:149–50.

    Article  Google Scholar 

  • McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs. 2004;18:933–56.

    Article  CAS  PubMed  Google Scholar 

  • Möller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacolgy. 1997;132:396–401.

    Article  Google Scholar 

  • Munk-Andersen E, Behnke K, Heltberg J, Nielsen H, Gerlach J. Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. Acta Psychiatr Scand Suppl. 1984;311: 31–41.

    Google Scholar 

  • Niskanen P, Tammninen T, Viukari M. Sulpiride vs. amitriptyline in the treatment of depression. Curr Ther Res. 1975;17:281–4.

    CAS  PubMed  Google Scholar 

  • Noble S, Benfield P. Amisulpride: a review of its clinical potential in dysthymia. CNS Drugs. 1999;12:471–83.

    Article  CAS  Google Scholar 

  • Nuss P, Hummer M, Tessier C. The use of amisulpride in the treatment of acute psychosis. Ther Clin Risk Manag. 2007;3:3–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pagsberg AK, Tarp S, Glintborg D, Stenstrøm AD, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adoles Psychiatry. 2017;56:191–202.

    Google Scholar 

  • Pani L, Gessa GL. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry. 2002;7:247–53.

    Article  CAS  PubMed  Google Scholar 

  • Peuskens J, Bech P, Möller HJ, Bale R, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res. 1999;88:107–17.

    Article  CAS  PubMed  Google Scholar 

  • Peuskens J, Möller HJ, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol. 2002;12:305–10.

    Article  CAS  PubMed  Google Scholar 

  • Pillinger T, McCutcheon RA, Yuya Mizuno VL, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77.

    Google Scholar 

  • Rama Rao VA, Bailey J, Bishop M, Coppen A. A clinical and pharmacodynamics evaluation of sulpiride. Psychopharmacology. 1981;73:77–80.

    Article  Google Scholar 

  • Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280:83–97.

    CAS  PubMed  Google Scholar 

  • Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47:43–52.

    Article  CAS  PubMed  Google Scholar 

  • Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study. J Affect Disord. 1998;48:47–56.

    Article  CAS  PubMed  Google Scholar 

  • Standish-Barry HM, Bouras N, Bridges PK, Watson JP. A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder. Psychopharmacology. 1983;81:258–60.

    Article  CAS  PubMed  Google Scholar 

  • Wang J, Sampson S. Sulpiride versus placebo for schizophrenia. Cochrane Database Syst Rev. 2014;4:CD007811.

    Google Scholar 

  • Wetzel H, Gründer G, Hillert A, Philipp M, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology. 1998;137:223–32.

    Article  CAS  PubMed  Google Scholar 

  • Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205–18.

    Article  CAS  PubMed  Google Scholar 

  • Zhu Y, Krause M, Huhn M, Rothe P, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017;4:694–705.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

Authors
  1. Gerd Laux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerd Laux .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Bayern, Germany

    Christian Riederer

Section Editor information

  1. Department of Psychiatry, University Hospital Leipzig, Leipzig, Germany

    Frank Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Laux, G. (2021). Amisulpride and Sulpiride in the Treatment of Psychosis. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_57-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_57-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation